Impact of Driver Genetic Alterations on Survival in Metastatic Colorectal Cancer Patients from a Genetically Homogeneous Sardinian Population: A Real-World Study
Authors:
- Grazia PalombaGrazia Palomba
- Luca NuvoliLuca Nuvoli
- Maria Cristina SiniMaria Cristina Sini
- Giovanni Battista MaestraleGiovanni Battista Maestrale
- Maria Grazia DoroMaria Grazia Doro
- Laura FrogheriLaura Frogheri
- Ivana PersicoIvana Persico
- Angelo ZinelluAngelo Zinellu
- Davide Adriano SanteufemiaDavide Adriano Santeufemia
- Panagiotis PaliogiannisPanagiotis Paliogiannis
- Daniele DeloguDaniele Delogu
- Fabrizio ScognamilloFabrizio Scognamillo
Open Access
Abstract
Background: Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. Recent therapeutic advancements have significantly improved clinical management, underscoring the importance of routine molecular profiling to guide personalised treatment strategies. This study aims to evaluate the prognostic impact of main molecular alterations—including allele frequency (AF) of RAS mutations—on survival outcomes in a real-world hospital-based cohort of patients with metastatic CRC. Methods: A total of 208 consecutive patients with a histologically confirmed diagnosis of CRC and complete clinical, molecular, and survival data were retrospectively analysed. Somatic mutations in KRAS, NRAS, BRAF, and the occurrence of microsatellite instability (MSI) were assessed using pyrosequencing and real-time PCR assays, respectively, on formalin-fixed, paraffin-embedded tumour samples. Associations between mutational status, clinicopathological parameters, and overall survival (OS) were evaluated. Results: Overall, 138 patients (66.3%) harboured at least one somatic mutation: 115 (55.3%) in KRAS, 8 (3.8%) in NRAS, and 15 (7.2%) in BRAF. MSI was detected in 17/208 (8.2%) patients. A statistically significant improvement in OS was observed in patients lacking mutations in any of the three genes—referred to as wild-type (WT) patients—with BRAF mutated cases showing the worst survival (p = 0.041). Increasing age at the time of first-line therapy for advanced disease stage was associated with a statistically significant increase in the hazard of death (p = 0.031). Conclusions: In the advanced disease stage, RAS/BRAF wild-type colorectal cancers were significantly associated with a survival advantage.Keywords
Funding Information
- Sardinian Regional Government
This publication has 47 references indexed in Scilit:
- Characteristics and Prognosis of Early‐Onset vs. Late‐Onset Colon Cancer: A Propensity Score Matching Analysis Based on HistologyCancer Medicine, 2026
- KRAS Variant Frequency and Colorectal Cancer–Specific Survival by Race and EthnicityJAMA Network Open, 2026
- Emerging Frontiers in Colorectal Cancer Therapy: From Targeted Molecules to Immunomodulatory Breakthroughs and Cell-Based ApproachesDigestive Diseases and Sciences, 2025
- Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatmentEuropean Journal of Cancer, 2022
- Clinicopathological and molecular characteristics of early-onset vs late-onset colorectal cancer according to tumor locationInternational Journal of Clinical Oncology, 2022
- Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based studyThe Lancet Oncology, 2021
- Mutation analysis of adenomas and carcinomas of the colon: Early and late driversGenes, Chromosomes and Cancer, 2018
- The impact of age on complications, survival, and cause of death following colon cancer surgeryBritish Journal of Cancer, 2017
- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2014
- Dichotomizing continuous predictors in multiple regression: a bad ideaStatistics in Medicine, 2005